---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-024560"
form_type: "8-K"
ticker: "REVB"
cik: "0001810560"
company_name: "REVELATION BIOSCIENCES, INC."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:32:22.986376+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Revelation Biosciences Q3 2022 net loss $1.2M; cash $6.2M, expects runway through June 2023

## Summary
- Net loss Q3 2022 $1.2M ($0.06/share) vs $3.0M ($0.48/share) in Q3 2021.
- Cash $6.2M at Sep 30, 2022, up from $1.3M at Dec 31, 2021; expects to fund ops through June 2023.
- Completed a $5.0M public offering.
- Licensed Vanderbilt IP for REVTx-100; positive preclinical data for REVTx-300 in acute kidney injury.
- Anticipates starting Phase 1a clinical study for REVTx-100 and REVTx-300.

## SEC filing metadata
- accession: 0000950170-22-024560
- form_type: 8-K
- ticker: REVB
- cik: 0001810560
- company_name: REVELATION BIOSCIENCES, INC.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810560/000095017022024560/0000950170-22-024560-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810560/000095017022024560/revb-20221110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-024560
- JSON: https://secwatch.observer/filing/0000950170-22-024560.json
- Plain text: https://secwatch.observer/filing/0000950170-22-024560.txt

## Key facts
- Earnings Releases
  REVELATION BIOSCIENCES, INC. reported the nine months ended September 30, 2022 results: net income $9.6 million, EPS $0.57 per share.
  - Period: the nine months ended September 30, 2022
  - Net income: $9.6 million
  - EPS: $0.57 per share
  - Result: reported results
  source text: Revelation’s net loss for the three and nine months ended September 30, 2022 was $1.2 million and $9.6 million, or $0.06 per share and $0.57 per share, respectively
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810560/000095017022024560/0000950170-22-024560-index.htm
- Earnings Releases
  REVELATION BIOSCIENCES, INC. reported the three months ended September 30, 2022 results: net income $1.2 million, EPS $0.06 per share.
  - Period: the three months ended September 30, 2022
  - Net income: $1.2 million
  - EPS: $0.06 per share
  - Result: reported results
  source text: Revelation’s net loss for the three and nine months ended September 30, 2022 was $1.2 million and $9.6 million, or $0.06 per share and $0.57 per share, respectively
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810560/000095017022024560/0000950170-22-024560-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.